Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME: AVP-923 for Central Neuropathic Pain in MS
NCT01324232Phase 2Completed
- Sponsor
- Avanir Pharmaceuticals
- Start
- Sep 2011
- Primary completion
- Sep 2013
- Modality
- Classical Binding Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of dextromethorphan + quinidine in central neuropathic pain (CNP), sponsored by Avanir Pharmaceuticals. Started Sep 2011; status: completed.
02
Drugs
dextromethorphan + quinidine
03
Conditions
central neuropathic pain (CNP)
Beyond the preview
Go deeper on NCT01324232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01324232.